Carticel®, autologous cultured chondrocytes for treatment of cartilage defects

Carticel® are autologous cultured chondrocytes isolated from the cartilage. Carticel® cells are used  to treat osteoarthritis and osteochondrosis and are specifically indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. In a clinically challenging patient population who suffered moderate-to-large chondral defects and who failed at least one prior cartilage treatment, Carticel® demonstrated long-term durability of up to 4 years and statistically significant and clinically meaningful reductions in pain and improvements in function.